FindTrial
Sign In

Efficacy of roxadustat versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study

Efficacy of roxadustat versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086902
Enrollment
Unknown
Registered
2024-07-15
Start date
2023-09-07
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis

Interventions

Roxadustat group:N/A
ESAs group:N/A

Sponsors

The Second Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 2022.12.7-2023.1.31 all patients undergoing peritoneal dialysis at our center

Exclusion criteria

Exclusion criteria: (1) patients who were transferred to renal transplantation during the follow-up period, (2) patients who had pulmonary infection caused by other diseases during the follow-up period and could not be differentiated from covid-19 pneumonia, and (3) patients who were treated with other anemia-correcting drugs

Design outcomes

Primary

MeasureTime frame
Hemoglobin;—

Secondary

MeasureTime frame
Total cholesterol;Compliance with medication;—

Countries

China

Contacts

Public ContactXinglei Zhou

The Second Affiliated Hospital of Xuzhou Medical University

dzhouxinglei@163.com+86 138 5209 1980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026